Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 49
Filter
1.
AIDS Res Ther ; 17(1): 22, 2020 05 20.
Article in English | MEDLINE | ID: mdl-32434561

ABSTRACT

BACKGROUND: Pre-treatment drug resistance (PDR) among antiretroviral drug-naïve people living with HIV (PLHIV) represents an important indicator for the risk of treatment failure and the spread of drug resistant HIV variants. We assessed the prevalence of PDR and treatment outcomes among adults living with HIV-1 in Lilongwe, Malawi. METHODS: We selected 200 participants at random from the Lighthouse Tenofovir Cohort Study (LighTen). Serum samples were drawn prior to treatment initiation in 2014 and 2015, frozen, and later analyzed for the presence of HIV-1 drug resistance mutations. Amplicons were sequenced and interpreted by Stanford HIVdb interpretation algorithm 8.4. We assessed treatment outcomes by evaluating clinical outcome and viral suppression at the end of the follow-up period in October 2019. RESULTS: PDR testing was successful in 197 of 200 samples. The overall NNRTI- PDR prevalence was 13.7% (27/197). The prevalence of intermediate or high level NNRTI- PDR was 11.2% (22/197). The most common mutation was K103N (5.6%, 11/197), followed by Y181C (3.6%, 7/197). In one case, we detected an NRTI resistance mutation (M184V), in combination with multiple NNRTI resistance mutations. All HIV-1 isolates analyzed were of subtype C. Of the 27 patients with NNRTI- PDR, 9 were still alive, on ART, and virally suppressed at the end of follow-up. CONCLUSION: The prevalence of NNRTI- PDR was above the critical level of 10% suggested by the Global Action Plan on HIV Drug Resistance. The distribution of drug resistance mutations was similar to that seen in previous studies from the region, and further supports the introduction of integrase inhibitors in first-line treatment in Malawi. Furthermore, our findings underline the need for continued PDR surveillance and pharmacovigilance in Sub-Saharan Africa.


Subject(s)
Drug Resistance, Viral/genetics , HIV-1/drug effects , HIV-1/genetics , Urban Population/statistics & numerical data , Adult , Anti-HIV Agents/therapeutic use , Cohort Studies , Drug Administration Schedule , Female , Genotype , HIV Infections/drug therapy , HIV Infections/epidemiology , Humans , Malawi/epidemiology , Male , Middle Aged , Mutation , Prevalence , Treatment Failure , Treatment Outcome , Viral Load/drug effects
2.
United European Gastroenterol J ; 5(5): 742-749, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28815039

ABSTRACT

BACKGROUND AND AIMS: Adenoma detection rate (ADR) has been established as a quality indicator for screening colonoscopy. Because ADR is cumbersome to obtain in routine practice, polyp detection rate (PDR), polypectomy rate (PR) and adenoma-to-polyp-detection-rate-ratio (APDRR) have been proposed to estimate ADR. This study aimed to evaluate APDRR in order to estimate ADR (ADRest) in different settings. METHODS: Average risk screening and surveillance colonoscopies from a community-based private practice and a tertiary academic hospital setting were retrospectively evaluated. APDRR was calculated as averaged group APDRR for all study procedures (APDRR) and for the first half of study procedures of each gastroenterologist (APDRRag) or individually for each gastroenterologist on the basis of his or her first 25, 50 and 100 colonoscopies (APDRRind). ADRest was determined from PDR by using APDRR, APDRRag, and APDRRind, respectively. RESULTS: A total of 2717 individuals were analyzed. Using APDRR, significant correlations between ADR and ADRest were observed for the entire (0.944, p < 0.001), proximal (0.854, p < 0.001), and distal (0.977, p < 0.001) colon. These correlations were lost when APDRRag was used to estimate each gastroenterologist's ADR for the second half of his or her included colonoscopies. However, ADR and ADRest correlated significantly with a root-mean-square-error of 6.8% and 5.8% when APDRRind on the basis of each gastroenterologist's first 50 and 100 colonoscopies was used for subsequent colonoscopies. CONCLUSIONS: ADR for subsequent colonoscopies of an individual endoscopist can be reliably estimated from PDR by using an individually calculated APDRR. Prospective studies are needed to verify this promising approach in different practice settings.

3.
Z Gastroenterol ; 54(10): 1168-1169, 2016 Oct.
Article in German | MEDLINE | ID: mdl-27723909

ABSTRACT

The S2k-Guideline "Helicobacter pylori and gastroduodenal ulcer disease" offers a statement and comment on the subject of stress ulcer prophylaxis that need a critical response.


Subject(s)
Helicobacter Infections , Receptors, Histamine H2 , Helicobacter pylori , Histamine H2 Antagonists , Humans , Peptic Ulcer , Proton Pump Inhibitors , Ulcer
4.
Z Gastroenterol ; 54(7): 642-6, 2016 Jul.
Article in English | MEDLINE | ID: mdl-27429101

ABSTRACT

PURPOSE: To investigate the effect of an early contrast-enhanced computed tomography (CECT) on clinical course and complications of acute pancreatitis (AP). MATERIAL AND METHODS: 58 patients with AP who had at least one CECT examination were analyzed retrospectively. Laboratory as well as clinical data, and results from the assessment of disease severity (CT severity index (CTSI) and its modified (MCTSI) version) were analyzed. The primary endpoint was the development of severe complications, defined as death, respiratory failure, acute renal failure, and the need for invasive interventions. Patients were divided into two groups: an early group (CECT within the first 48 h after the onset of symptoms, n = 32) and a late group (CECT > 48 h after the onset of symptoms, n = 26). Multivariate regression analysis was performed to identify risk factors for severe complications. RESULTS: There were no statistically significant differences between both groups concerning baseline characteristics, CTSI, and MCTSI. Complications occurred more often in the early CECT group (p = 0.008). Multivariate logistic regression analysis identified an early CECT and a severe MCTSI as independent risk factors for the occurrence of severe complications (p = 0.02 and p = 0.002, respectively). CONCLUSION: CECT performed within the first 48 h after the onset of symptoms is associated with an unfavorable outcome in AP.


Subject(s)
Acute Kidney Injury/mortality , Early Diagnosis , Pancreatitis/diagnostic imaging , Pancreatitis/mortality , Respiratory Insufficiency/mortality , Tomography, X-Ray Computed/statistics & numerical data , Acute Disease , Acute Kidney Injury/diagnosis , Adult , Aged , Aged, 80 and over , Contrast Media , Disease Progression , Female , Germany/epidemiology , Humans , Length of Stay/statistics & numerical data , Male , Middle Aged , Pancreatectomy/mortality , Pancreatectomy/statistics & numerical data , Pancreatitis/surgery , Reproducibility of Results , Respiratory Insufficiency/diagnosis , Retrospective Studies , Risk Factors , Sensitivity and Specificity , Survival Rate , Young Adult
6.
Infection ; 43(2): 153-62, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25701223

ABSTRACT

PURPOSE: We studied a cohort of adult patients with chronic hepatitis B (CHB) infection, followed at a tertiary referral liver center in Germany over 12.5 years to analyze the clinical features and impact of management on disease progression and survival of CHB patients in general and of those with CHB and HCC in particular. METHODS: We retrospectively evaluated the medical records of 242 adult (age ≥ 18 years) patients. CHB was defined as positive hepatitis B surface antigen (HBsAg) and/or HBV-DNA levels >10 IU/mL for at least 6 months. Patient demographics, HBV markers, antiviral treatment, laboratory parameters, liver imaging and histology were recorded for each visit. HCC patients were divided into two groups and separately analyzed (group 1: n = 24, HCC at first visit and group 2: n = 11, HCC during surveillance). RESULTS: The mean age was 44 years in CHB patients without HCC (63% male) and about 59 years in patients with HCC (77% male). Antiviral therapy was given to 59% of patients without HCC compared to only 25% in group 1 and 18% in group 2 with comparable median HBV DNA levels of approximately 36,000 IU/mL. There was no statistically significant difference concerning the HCC stages (Milan, UCSF, BCLC) at first diagnosis. Five-year survival was 19% in group 1 vs. 64% in group 2 (p = 0.019), with LTx performed in 12 vs. 45%, respectively. CONCLUSION: Surveillance of CHB patients did not result in early stage detection of HCC but in a higher likelihood to receive potentially curative treatments.


Subject(s)
Disease Management , Hepatitis B, Chronic/diagnosis , Hepatitis B, Chronic/drug therapy , Adult , Carcinoma, Hepatocellular/diagnosis , Carcinoma, Hepatocellular/epidemiology , Carcinoma, Hepatocellular/etiology , Carcinoma, Hepatocellular/mortality , Female , Follow-Up Studies , Germany , Hepatitis B, Chronic/complications , Hepatitis B, Chronic/mortality , Humans , Liver Cirrhosis/etiology , Liver Cirrhosis/pathology , Liver Neoplasms/diagnosis , Liver Neoplasms/epidemiology , Liver Neoplasms/etiology , Liver Neoplasms/mortality , Male , Middle Aged , Outcome Assessment, Health Care , Population Surveillance , Registries , Retrospective Studies , Tertiary Care Centers
9.
Z Gastroenterol ; 45(4): 307-12, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17427113

ABSTRACT

BACKGROUND: The sensitivity of endosonography for pancreatic tumors is good, but differentiation between malignant and benign lesions remains a challenge. We, therefore, analyzed the correlation between endosonographic findings and pancreatic carcinoma in a population with a high prevalence of chronic pancreatitis. METHODS: 171 endosonographic examinations were retrospectively evaluated using 22 dichotomous criteria. Final diagnosis was defined by the results of pancreas resection or by clinical follow-up (median: 41 months). A sum score was established after multivariate analysis. RESULTS: Final diagnosis was carcinoma, chronic pancreatitis, neuroendocrine tumor and normal pancreas in 67, 65, 9, and 38 subjects (prevalence 39 %, 38 %, 5 %, 22 % respectively) After multivariate analysis, carcinoma was significantly correlated with six endosonographic criteria and age, which resulted in the following score (yes = 1, no = 0): (dilated pancreatic duct) + (vascular infiltration) + (suspicious lymph nodes) + (tumor edge with pseudopodia-like extensions) + (age > 50 years) - (increased pancreas parenchyma echogenicity) - (tumor diameter < 10 mm) + 3. After receiver operating characteristic analysis, the area under the curve was 0.85. For score values of 5 (4) or more, sensitivity was 0.63 (0.93), specificity 0.91 (0.55), positive predictive value 0.82 (0.57), negative predictive value 0.79 (0.92), positive likelihood ratio 7.24 (2.05), and negative likelihood ratio 0.41 (0.14). CONCLUSION: A simple and potentially useful score for the prediction of pancreatic cancer based on six endosonographic criteria and patient age was established. Distribution of final diagnoses in the patient population argues for the score's applicability in clinical practice of a tertiary referral center and warrants prospective validation.


Subject(s)
Carcinoma, Neuroendocrine/diagnostic imaging , Endosonography , Pancreatic Neoplasms/diagnostic imaging , Adolescent , Adult , Aged , Aged, 80 and over , Carcinoma, Neuroendocrine/surgery , Diagnosis, Differential , Female , Follow-Up Studies , Humans , Lymphatic Metastasis/diagnostic imaging , Male , Middle Aged , Neoplasm Invasiveness/diagnostic imaging , Pancreas/diagnostic imaging , Pancreatic Neoplasms/surgery , Pancreatitis, Chronic/diagnostic imaging , Pancreatitis, Chronic/surgery , ROC Curve , Referral and Consultation , Retrospective Studies , Sensitivity and Specificity
10.
Curr Med Chem ; 13(30): 3649-61, 2006.
Article in English | MEDLINE | ID: mdl-17168728

ABSTRACT

Morbidity and mortality of chronic liver disease are primarily caused by liver cirrhosis and portal hypertension, both of them secondary disorders of progressive liver fibrosis. The main fibrogenic cell type in the liver, the hepatic stellate cell (HSC), is activated and stimulated by several factors, among which the renin-angiotensin-aldosterone system (RAAS) plays a major role. Angiotensin II induces various profibrotic pathways via the angiotensin II receptor type 1 (AT(1) receptor) not only in heart and kidney, but also in liver tissue. Stimulation of the AT(1) receptor promotes the transformation of the quiescent HSC into the myofibroblast like activated HSC and the synthesis of transforming growth factor-beta1 (TGF-beta), the major profibrotic cytokine in the liver. In addition, aldosterone has been suggested to induce profibrotic effects in chronic heart and liver disease. This review focuses on the concept that inhibitors of the RAAS retard or even reverse liver fibrosis and reduce portal hypertension. Angiotensin converting enzyme (ACE) inhibitors, AT(1) receptor antagonists, and aldosterone antagonists have been demonstrated to reduce the proliferation of HSC, to decrease the synthesis of profibrotic molecules, and to have the potential to improve liver fibrosis. However, side-effects such as systemic hypotension may impair the clinical application of RAAS inhibitors in patients with liver cirrhosis and portal hypertension. Also, efficacy may be limited by the downregulation of AT(1) receptors in advanced fibrosis, which has been observed in animal and human studies. Randomized clinical studies are essential to evaluate, whether this approach is beneficial in patients with chronic liver disease and progressive fibrosis.


Subject(s)
Hypertension, Portal/physiopathology , Liver Cirrhosis/physiopathology , Renin-Angiotensin System/drug effects , Drug Design , Humans , Liver/physiopathology
12.
Z Gastroenterol ; 41(11): 1083-6, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14648377

ABSTRACT

Since survival rates of fulminant liver failure are low, early consideration of liver transplantation in patients developing hepatic encephalopathy due to progressive liver failure is mandatory. Rapid diagnostic work-up is necessary to identify the underlying disease and to rule out contraindications to liver transplantation. We report the case of a 35-year-old patient presenting with fulminant hepatitis and a four-week history of biopsy-proven autoimmune hepatitis. Despite high-dose steroid-treatment liver function progressively worsened and hepatic encephalopathy rapidly developed. Histopathologic evaluation of a liver biopsy specimen revealed necrotizing hepatitis and rare atypical lymphocytes. Surgical biopsy specimens confirmed the suspicion of an aggressive hepatosplenic alphabeta T-cell lymphoma which represents a contraindication to liver transplantation.


Subject(s)
Liver Failure/etiology , Liver Neoplasms/complications , Lymphoma, T-Cell/complications , Splenic Neoplasms/complications , Adult , Biopsy , Hepatic Encephalopathy/etiology , Hepatic Encephalopathy/mortality , Hepatitis/pathology , Hepatitis, Autoimmune/complications , Hepatitis, Autoimmune/pathology , Humans , Immunohistochemistry , Laparotomy , Liver/pathology , Liver Failure/mortality , Liver Neoplasms/diagnosis , Liver Neoplasms/pathology , Lymphoma, T-Cell/diagnosis , Lymphoma, T-Cell/pathology , Male , Spleen/pathology , Splenic Neoplasms/diagnosis , Splenic Neoplasms/pathology
13.
Rofo ; 174(6): 767-75, 2002 Jun.
Article in German | MEDLINE | ID: mdl-12063609

ABSTRACT

BACKGROUND: In 1994, 5 % of a total of 25 718 examinations and 7 % of all 4630 B-mode sonograms performed in the Radiology Department, University of Cologne was classified as not indicated. In light of these results, the health care policy guidelines for sonographic indications have been amended. PURPOSE: The aim of this study was to establish the current rate of non-indicated sonographic examinations performed in routine diagnostics by radiology departments at university hospitals, to determine the reasons for such over-diagnosis and identify which regulatory mechanisms can be implemented to prevent his. METHOD: We counted the number of 1) B-mode and 2) color-flow Doppler ultrasound imaging procedures carried out in patients who had had no change in symptoms within the previous 4 weeks or who were scheduled without reference to an existing sonogram (double examinations). 3) The reasons for over-diagnosis were analyzed. 4) The 1994 survey was repeated in 2000 with an identical protocol and 5) additionally, a modified survey of the diagnostic questions was conducted. RESULTS: 1) Out of 4,119 patients presenting for the first time to receive a B-mode sonogram, 443 prior sonograms (11 %), 305 CT scans (7 %) and 57 MRI scans (1 %) were documented. 2) Double sonograms were carried out in 6 % of the 1,118 patients presenting for the first time for color-flow Doppler ultrasounds and in 16 % of the 651 patients assigned to receive catheter angiographies with arterial color-flow Doppler. 2) 41 out of 55 (75 %) prior sonograms from non-university settings stated by 94 surgery patients were listed in the medical records. 36 out of 43 (84 %) prior sonograms from the university hospital were repeated in the same patients despite the fact that the medical report with the findings was available. None of the 48 sonograms indicated to confirm a plausible finding yielded any information that was additionally relevant to therapy. 4) In the period April - June, 2000, 12 % of all 15,921 tests and interventions, 26 % of 3,569 B-mode sonograms and 58 % of 1,033 abdominal sonograms performed in adults were classified as having not been indicated. 5) Staging and follow-up were stated as the most common reasons that a sonography was carried out in 46 % of the 1,017 adults who were given B-mode sonograms conducted from Jan - Mar, 2000 and comprised 62 % of the 410 sonograms classified as not or probably not medically indicated. CONCLUSION: The results showed that a multidisciplinary consensus was required to establish the diagnostic value of sonographic procedures. Therefore, this research group drafted a hospital-internal interdisciplinary guideline for "abdominal transcutaneous B-mode sonography in oncological questions".


Subject(s)
Health Services Misuse/statistics & numerical data , National Health Programs/statistics & numerical data , Radiology Department, Hospital/statistics & numerical data , Ultrasonography, Doppler, Color/statistics & numerical data , Ultrasonography/statistics & numerical data , Diagnostic Imaging/statistics & numerical data , Female , Germany , Humans , Male , Neoplasm Staging , Neoplasms/diagnostic imaging , Neoplasms/pathology , Practice Guidelines as Topic , Utilization Review
15.
Lancet ; 355(9204): 652-3; author reply 653, 2000 Feb 19.
Article in English | MEDLINE | ID: mdl-10697003
16.
Z Arztl Fortbild Qualitatssich ; 93(6): 447-53, 1999 Aug.
Article in German | MEDLINE | ID: mdl-10519194

ABSTRACT

Eighteen clinical practice guidelines on interdisciplinary diagnostic issues were developed at the University Hospital of Cologne, Germany. The guideline committee is organized and directed by the quality control program, which also includes the local Cochrane initiative and a wide range of organizational topics. During guideline development, questions of differential diagnosis were addressed to the same extent as the organizational and financial realization. Broad consideration was given to medicolegal implications, but need for interspecialty cooperation was judged to be more critical and even more relevant in this regard. Guidelines were primarily developed as algorithms and translated to text versions secondarily. Critical steps in the decision tree were supported by rated literature and recommendations weighte by criteria as used in evidence-based medicine. For implementation, guidelines were presented to colleagues in a series of short lectures, as print versions containing all literature used in the developing process, and in hypertext format, which is accessible via intranet. Three levels of presentation were chosen in the html-version: algorithm, decision, and information. The former is due to orientation in the guideline, the second displays the binary question, and the latter makes the scientific background available, together with literature and links for more information. Efforts to check effectiveness are currently been made, questions of efficiency will be addressed in future.


Subject(s)
Algorithms , Clinical Medicine/standards , Diagnosis , Diagnosis, Differential , Germany , Humans , Quality Assurance, Health Care
18.
J Clin Microbiol ; 35(8): 2168-9, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9230408

ABSTRACT

Homosexual persons or human immunodeficiency virus (HIV)-infected patients frequently excrete cysts of nonpathogenic strains of Entamoeba histolytica ("Entamoeba dispar"). However, invasive amoebiasis is rare. We report two patients with AIDS and cytomegalovirus colitis in whom invasive amoebiasis was histologically diagnosed. It is concluded that E. histolytica has to be considered in HIV-infected patients with colitis.


Subject(s)
AIDS-Related Opportunistic Infections/complications , Acquired Immunodeficiency Syndrome/complications , Amebiasis/complications , Colitis/complications , Cytomegalovirus Infections/complications , AIDS-Related Opportunistic Infections/parasitology , AIDS-Related Opportunistic Infections/virology , Adult , Animals , Colitis/virology , Entamoeba histolytica/pathogenicity , Humans , Immunocompromised Host , Male , Middle Aged
19.
Z Gastroenterol ; 34(11): 753-6, 1996 Nov.
Article in German | MEDLINE | ID: mdl-9045537

ABSTRACT

A 20 year old male patient with a four-years-history of moderately active ulcerative colitis was admitted due to extensive generalized edema. He suffered from a nephrotic syndrome, which was caused by secondary renal amyloidosis due to the colitis. Under continuous low dose therapy with colchicine in addition to the usual colitis therapy proteinuria decreased from values above 10 g/die to about 3 g/die and edema disappeared completely. Secondary amyloidosis following inflammatory bowel disease is a rare event, in case of ulcerative colitis a true curiosity. Cases published so far are discussed.


Subject(s)
Amyloidosis/drug therapy , Colchicine/administration & dosage , Colitis, Ulcerative/complications , Kidney Diseases/drug therapy , Adult , Amyloidosis/diagnosis , Colitis, Ulcerative/drug therapy , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Therapy, Combination , Humans , Hydrocortisone/therapeutic use , Kidney Diseases/diagnosis , Kidney Function Tests , Male
SELECTION OF CITATIONS
SEARCH DETAIL